Loading...
In two industry-sponsored, randomized, international trials, investigators examined the effect of dipeptidyl peptidase–4 (DPP-4) inhibitors on the primary endpoint of cardiovascular-related death, myocardial infarction, or stroke in patients with type 2 diabetes. The studies were conducted in response to the FDA's requirement that cardiovascular safety be demonstrated for new diabetes drugs.
In one trial, 16,500 patients (mean age, 65; median duration of diabetes, 10 years) with additional cardiovascular risk factors or known cardiovascular disease received saxagliptin (Onglyza) or placebo. During average follow-up of 2 years, the primary endpoint occurred with near-identical frequency in the two groups (7.3% and 7.2%). No differences in sec…